Cellectis S.A. (CLLS) Financials

CLLS Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 209.7 million 133.6 million
2023-06-30 227.7 million 131.1 million
2023-03-31 251.4 million 130.9 million
2022-12-31 261.2 million 135.3 million

CLLS Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -17.4 million -2.7 million
2023-06-30 -19.3 million 1.6 million
2023-03-31 -28.5 million 1.6 million
2022-12-31 1.7 million -2.7 million

CLLS Net Income

No data available :(

CLLS Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 67.4 million - 52.0 million
2023-06-30 85.5 million - 54.4 million
2023-03-31 88.2 million - 56.5 million
2022-12-31 97.7 million - 57.2 million

CLLS Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 55.6 million
2023-06-30 55.6 million
2023-03-31 51.5 million
2022-12-31 45.4 million

CLLS Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 314000 18.9 million 1.6 million -
2023-06-30 270000 22.1 million 2.7 million 1.3 million
2023-03-31 213000 21.1 million 2.1 million 728000
2022-12-31 2.9 million 21.4 million 17.7 million 16.0 million

CLLS Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 155000 181000
2023-06-30 178000 55000
2023-03-31 139000 334000
2022-12-31 16.0 million 690000

CLLS

Price: $2.99

52 week price:
0.96
3.77

Earnings Per Share: -1.41 USD

P/E Ratio: -2.13

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Volume: 1.9 million

Ebitda: -29.3 million

Market Capitalization: 193.0 million

Links: